Longitudinal multi-omics profiling of tofacitinib response identifies a pre-existing Janus kinase-tractable inflammatory state in ulcerative colitis

Baseline and longitudinal multi-omics profiling reveal a pre-existing JAK-tractable inflammatory state in ulcerative colitis patients responding to tofacitinib.

• Why it matters: Understanding the biological basis of treatment response can improve personalized therapies for UC, addressing variability in patient outcomes and identifying predictive biomarkers.
• What they did: The study analyzed transcriptomics and proteomics data from intestinal biopsies, blood, and serum in UC patients before and during tofacitinib treatment, involving multiple time points.
• The result: Findings show that a specific inflammatory state predates treatment and predicts response, enabling targeted interventions and better patient stratification in UC management.